A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease

Table 1

The feature Table 1 of meta-analysis.

Study	Number (Exp/Con)		Gender (Exp/Con)		Age (Exp/Con)		Course of disease/ year (Exp/Con)
Qing Shi 2018[21]	93	93	50/43	54/39	60.21±3.97	59.43±3.65	-	-
Wenjun Gao 2018[22]	40	40	24/16	22/18	64.92±6.40	65.28±6.39	6.18 ±1.23	6.20 ±1.21
Chunyan Xue 2017[23]	40	40	28/12	26/14	61.35±2.64	61.42±2.71	-	-
Guangzhi Li 2017[24]	44	39	32/12	27/12	71.05±3.83	72.67±4.17	15.12±3.95	14.26 ± 4. 97
Jianhua Guo 2016[25]	70	70	43/27	46/24	77.60±5.40	76.80±5.30	9.20±0.30	11.50±0.50
Jing Feng 2016[26]	260	260	165/95	157/103	63.88±2.85	63.85±2.79	5.88±4.70	5.81±2.79
Qianfan Zhao 2016[27]	60	60	32/28	33/27	53.25±7.15	54.60±7.25	6.34±2.79	6.53±2.68
Yunyu Zhou 2016[28]	30	30	18/12	17/13	60.40±5.20	61.50±5.10	-	-
Yingjie Li 2016[29]	60	60	38/22	36/24	73.3±3.5	72.7±3.6	-	-
Yihao Wang 2016 [30]	48	48	60/36		62.30±5.40		-	-
Yongjie Qiao 2016[31]	40	40	28/12	26/14	52.36±12.67	53.06±13.04	7. 89±2. 86	8. 17±2. 44
Lingzhun Wang 2016[32]	30	30	37/23		65.12±9.760		5.35±1.56
Qicai Fan 2015[33]	48	42	30/18	28/14	60.80±5.80	62.30±8.60	-	-
Wei Xu 2015[34]	46	46	29/17	31/15	65.89±7.21	66.14±6.58	5.72±3.96	6.41±4.08
Hengdong Liu 2015[35]	33	33	18/15	17/16	70.30±2.30	70.50±2.10	5.50± 1.20	5.4 0± 1.30
Zhimei Huang 2015[36]	90	78	48/42	42/36	74.20±4.10	73.70±4.30	3.30± 1.20	3.50± 1.50
Jing Li 2015[37]	55	55	38/17	36/19	56.58±6.36	57.32±6.33	5.23±0.78	5.41±0.72
Lei Xie 2014[38]	40	40	23/17	25/15	46.00±87.00	42.00±86.00	-	-
Ting Li 2014[39]	85	52	52/33	37/15	68.20±2.40	64.90±3.20	13.70±1.50	11.50±1.80
Hongbin Cai 2013[40]	34	35	17/17	20/15	56.79±5.89	57.02±7.50	12.77±5.30	11.89±4.39
Yongping Hu 2012[41]	35	35	17/18	19/17	55.54±5.42	52.46±5.01	-	-
Tingzhu Wu 2010[42]	43	37	48/32		65.10±10.40		-	-